PURPOSECannabis has been legalized across multiple states over the past decade; however, its use among cancer survivors ...

Health care delays (postponement of medical care) are a significant barrier to optimal care for cancer survivors, particularly among adolescent and young adults (AYAs). 1 - 3 Despite overall ...

Among 121 total families with LFS at our institutions, 17 patients from 16 (13%) families diagnosed with LFS had an HM. A literature review found an additional 83 patients with detailed descriptions, ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

As a cancer of the immune system, lymphoma exhibits clinical features and treatment strategies that differ markedly from those of solid tumors. Lymphoma uniquely exhibits a bimodal age distribution, ...

JCO invites you to enter our first Art of Oncology Narrative Medicine Contest for early career oncologists. Entries will be accepted through August 31, 2025. Finalists will be judged by a panel of ...

Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase three ...

Pancreatic cancer is soon to be the second leading cause of cancer-related death in the United States. 1 Despite this reality, it is undeniable that there have been improvements in the management of ...

In 2025, ASCO published a guideline update on the use of sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer (stages I and II) treated with up-front breast-conserving surgery.

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

During 2009-2015, 1,094 patients were registered. After excluding ineligible patients, 302 and 753 patients were included in the SURF-RCT (surgery, n = 150; RFA, n = 152) and SURF-Cohort trial ...

We herein report on 60 newly diagnosed IC-ineligible patients treated at our institution with triplet regimens for isocitrate dehydrogenase (IDH)–mutant AML. Patients received either AZA + VEN + IVO ...